3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
37
Neoplasm Metastasis
2
Breast Diseases
2
Luminal B/HER2-negative Breast Cancer
1
Hormone Receptor Positive Breast Carcinoma
1
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1
HR+/HER2- Early Breast Cancer
1
HR+/HER2+ Early Breast Cancer
1
Estrogen Receptor and/or Progesterone Receptor Positive
1
Endometrial Stromal Tumors
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Breast Cancer Female
1
Arthralgia
1
Advanced Breast Cancer
1
Interventions
Tamoxifen
2
Paclitaxel
2
pyrotinib
1
pembrolizumab
1
palbociclib
1
iniparib
1
darolutamide
1
Thioctic Acid
1
Pentoxifylline
1
Metformin
1
Letrozole
1
Doxorubicin
1
Cyclophosphamide
1
Capecitabine
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Breast Cancer Female
×
Aromatase Inhibitors
×
Clear all
NCT03917082
2023-06-15
LALEAST
British Columbia Cancer Agency
Phase 2
Active not recruiting
290 enrolled